Citizens sees blockbuster potential in MBX Biosciences (MBX) post phase 2 data
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $61.00 price target on MBX Biosciences Inc (NASDAQ: MBX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
